<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159859">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02025894</url>
  </required_header>
  <id_info>
    <org_study_id>2010-01</org_study_id>
    <secondary_id>2010-A01064-35</secondary_id>
    <nct_id>NCT02025894</nct_id>
  </id_info>
  <brief_title>Risk Factors for Thromboembolic and Infectious Complications Related to Percutaneous Central Venous Catheters in Cancer - Prospective Multicenter Study</brief_title>
  <acronym>ONCOCIP</acronym>
  <official_title>Risk Factors for Thromboembolic and Infectious Complications Related to Percutaneous Central Venous Catheters in Cancer - Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de la Loire</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify risk factors for thromboembolic and /or infectious
      complications in 3,000  patients with solid tumor and receiving a Percutaneous Central
      Venous Catheter (PCVC).  A better understanding of the risk factors for these complications
      in this population would then allow interventional studies to be proposed to assess the
      benefit of prophylactic procedures in a sub-group of patients at most risk.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Thromboembolic complications:</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Locoregional or disseminated infectious complications:</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medical and economic consequences of these complications</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>PCVCs</arm_group_label>
    <description>Cohort of cancer patients with indication PCVC under the usual practice</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive patient
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a neoplastic solid tumour with an indication for insertion of a PCVC.

        Exclusion Criteria:

          -  Haematological neoplasm pathology, PCVC removal scheduled within 2 weeks of
             insertion,

          -  Therapeutic doses of anticoagulants required at inclusion,

          -  PCVC inserted by the femoral vein
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Fournel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Cancérologique Lucien Neuwirth</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hervé DECOUSUS, MDPhD</last_name>
    <role>Study Director</role>
    <affiliation>CIC - CHU DE SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franck CHAUVIN, MDPhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut cancérologique Lucien Neuwirth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hervé DECOUSUS, MDPhD</last_name>
    <phone>+330477120469</phone>
    <email>herve.decousus@chu-st-etienne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH d'Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Quint</last_name>
      <email>iquint@ch-annecy.fr</email>
    </contact>
    <investigator>
      <last_name>Laeticia Stéphanie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Intercommunal Annemasse-Bonneville</name>
      <address>
        <city>Annemasse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laeticia Maximim</last_name>
      <email>l-maximim@ch-hopitauxduleman.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick Chatelain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Savoie</name>
      <address>
        <city>Annemasse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laeticia Maximin</last_name>
      <email>l-maximin@ch-hopitauxduleman.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique Loiseau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Chambéry</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie CHAISSAC</last_name>
      <email>anne-marie.chaissac@ch-chambery.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Cauvin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pôle Santé république</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quentin Mazuyer</last_name>
      <email>qmasuyer@polesanterepublique.com</email>
    </contact>
    <investigator>
      <last_name>Jean-Paul Désir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muriel Durand</last_name>
      <email>mdurand@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick Merle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Feurs</name>
      <address>
        <city>Feurs</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine TARDY</last_name>
      <email>tardy.christine@ch-feurs.fr</email>
    </contact>
    <investigator>
      <last_name>Christelle Portois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Daniel Hollard</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique Alcalay</last_name>
      <email>v.alcalay@ghm-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile Leyronnas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH EmileRoux</name>
      <address>
        <city>Le Puy en Velay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Monange, MD</last_name>
      <email>brigitte.monange@ch-lepuy.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte Monange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Portes du Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Leveau</last_name>
      <email>b.leveau@clinique-mutualiste-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Magali Serine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Taïeb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Joseph Saint-Luc</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Armand</last_name>
      <email>sarmand@ch-stjoseph-stluc-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Cattey-Javouhey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie BLANCHET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Eugène André</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Leveau</last_name>
      <email>b.leveau@clinique-mutualiste-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Zoher Merad-Boudia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline Leclerc</last_name>
      <email>celine.leclerc@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gil Dubernard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Jean-Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Martin, MD</last_name>
      <phone>+33-437538725</phone>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infirmerie Protestante</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karima Brahmi</last_name>
      <email>recherche-clinique@infirmerie-protestante.fr</email>
    </contact>
    <investigator>
      <last_name>David TAVAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Desgenettes</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Clinique de la sauvergarde</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rama Sappey</last_name>
      <email>ramasappey@voila.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Moullet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Gerentet</last_name>
      <email>christine.gerentet@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Véronique Triller-Lenoir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Montbrison</name>
      <address>
        <city>Montbrison</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilbert Soglu, MD</last_name>
      <phone>+33-477967850</phone>
    </contact>
    <investigator>
      <last_name>Gilbert Soglu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Roanne</name>
      <address>
        <city>Roanne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel Vincent, MD</last_name>
      <phone>+33-477443384</phone>
    </contact>
    <investigator>
      <last_name>Lionel Vincent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Cancérologique Lucien neuwirth</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pierre</last_name>
      <email>mickael.pierre@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Forunel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Pays du Gier</name>
      <address>
        <city>Saint-Chamond</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale Ibanez, MD</last_name>
      <email>p.ibanez@chpg.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale Ibanez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne Service de Gynécologie</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pierre</last_name>
      <email>mickael.pierre@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Céline Chauleur, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne Service de Gastroentérologie</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pierre</last_name>
      <email>mickael.pierre@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc Phelip, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital privé de la Loire</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pierre</last_name>
      <email>mickael.pierre@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Muron, MDPhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux du Léman</name>
      <address>
        <city>Thonon-les-bains</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaelle Landry</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Romand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Drôme Ardèche</name>
      <address>
        <city>Valence</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde ROHFRITSCH</last_name>
      <email>m.rohfritsch@gsante.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu Bosset, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. doi: 10.1056/NEJMoa1108898.</citation>
    <PMID>22335737</PMID>
  </reference>
  <reference>
    <citation>Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Büller HR, Bounameaux H. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013 Jan;11(1):71-80. doi: 10.1111/jth.12071. Review.</citation>
    <PMID>23217208</PMID>
  </reference>
  <reference>
    <citation>Saber W, Moua T, Williams EC, Verso M, Agnelli G, Couban S, Young A, De Cicco M, Biffi R, van Rooden CJ, Huisman MV, Fagnani D, Cimminiello C, Moia M, Magagnoli M, Povoski SP, Malak SF, Lee AY. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost. 2011 Feb;9(2):312-9. doi: 10.1111/j.1538-7836.2010.04126.x.</citation>
    <PMID>21040443</PMID>
  </reference>
  <reference>
    <citation>Akl EA, Kamath G, Yosuico V, Kim SY, Barba M, Sperati F, Cook DJ, Schünemann HJ. Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer. 2008 Jun;112(11):2483-92. doi: 10.1002/cncr.23479. Review.</citation>
    <PMID>18404702</PMID>
  </reference>
  <reference>
    <citation>Mollee P, Jones M, Stackelroth J, van Kuilenburg R, Joubert W, Faoagali J, Looke D, Harper J, Clements A. Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study. J Hosp Infect. 2011 May;78(1):26-30. doi: 10.1016/j.jhin.2011.01.018. Epub 2011 Apr 2.</citation>
    <PMID>21459476</PMID>
  </reference>
  <reference>
    <citation>Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost. 2008 Jan;99(1):38-43. doi: 10.1160/TH07-07-0446. Review.</citation>
    <PMID>18217132</PMID>
  </reference>
  <reference>
    <citation>Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008 Nov 24;168(21):2377-81. doi: 10.1001/archinte.168.21.2377.</citation>
    <PMID>19029504</PMID>
  </reference>
  <reference>
    <citation>Schwarz RE, Groeger JS, Coit DG. Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis. Cancer. 1997 Apr 15;79(8):1635-40.</citation>
    <PMID>9118051</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 31, 2013</lastchanged_date>
  <firstreceived_date>December 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoplastic solid tumour</keyword>
  <keyword>PCVC</keyword>
  <keyword>thromboembolic complications</keyword>
  <keyword>infectious complications</keyword>
  <keyword>risk factors</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
